Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW Australia; Dendritic Cell Research, ANZAC Research Institute, Concord, NSW Australia.
Dendritic Cell Research, ANZAC Research Institute, Concord, NSW Australia; Sydney Medical School, The University of Sydney, Sydney, NSW Australia.
Semin Cell Dev Biol. 2019 Feb;86:77-88. doi: 10.1016/j.semcdb.2018.02.015. Epub 2018 Mar 21.
The ability of immune therapies to control cancer has recently generated intense interest. This therapeutic outcome is reliant on T cell recognition of tumour cells. The natural function of dendritic cells (DC) is to generate adaptive responses, by presenting antigen to T cells, hence they are a logical target to generate specific anti-tumour immunity. Our understanding of the biology of DC is expanding, and they are now known to be a family of related subsets with variable features and function. Most clinical experience to date with DC vaccination has been using monocyte-derived DC vaccines. There is now growing experience with alternative blood-derived DC derived vaccines, as well as with multiple forms of tumour antigen and its loading, a wide range of adjuvants and different modes of vaccine delivery. Key insights from pre-clinical studies, and lessons learned from early clinical testing drive progress towards improved vaccines. The potential to fortify responses with other modalities of immunotherapy makes clinically effective "second generation" DC vaccination strategies a priority for cancer immune therapists.
免疫疗法控制癌症的能力最近引起了极大的兴趣。这种治疗效果依赖于 T 细胞识别肿瘤细胞。树突状细胞 (DC) 的自然功能是通过向 T 细胞呈递抗原来产生适应性反应，因此它们是产生特异性抗肿瘤免疫的合理靶点。我们对 DC 生物学的理解正在不断扩展，现在已知它们是一组具有不同特征和功能的相关亚群。迄今为止，DC 疫苗接种的大多数临床经验都是使用单核细胞衍生的 DC 疫苗。现在，越来越多的人使用替代的血液衍生的 DC 衍生疫苗，以及多种形式的肿瘤抗原及其负载、广泛的佐剂和不同的疫苗传递方式。临床前研究的关键见解和早期临床测试的经验教训推动了改进疫苗的进展。利用其他免疫疗法模式来增强反应的潜力使具有临床疗效的“第二代”DC 疫苗接种策略成为癌症免疫治疗师的优先事项。
